Biology Reference
In-Depth Information
Barnes PJ, Liu SF (1995) Regulation of pulmonary vascular tone. Pharmacol Rev 47:87-131
Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to
clinical use. Pharmacol Rev 58:488-520
Black SM, Sanchez LS, Mata-Greenwood E, Bekker JM, Steinhorn RH, Fineman JR (2001) sGC
and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hyper-
tension. Am J Physiol Lung Cell Mol Physiol 281:L1051-L1057
Bogaard HJ, Abe K, Vonk Noordegraaf A, Voelkel NF (2009) The right ventricle under pressure:
cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest
135:794-804
Botha P, Parry G, Dark JH, Macgowan GA (2009) Acute hemodynamic effects of intravenous
sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5
inhibition. J Heart Lung Transplant 28:676-682
Chaouat A, Coulet F, Favre C, Simonneau G, Weitzenblum E, Soubrier F, Humbert M (2004)
Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and
dexfenfluramine associated pulmonary arterial hypertension. Thorax 59:446-448
Clarke WR, Uezono S, Chambers A, Doepfner P (1994) The type III phosphodiesterase inhibitor
milrinone and type V PDE inhibitor dipyridamole individually and synergistically reduce
elevated pulmonary vascular resistance. Pulm Pharmacol 7:81-89
Cohen AH, Hanson K, Morris K, Fouty B, McMurty IF, Clarke W, Rodman DM (1996) Inhibition
of cyclic 3
0
-5
0
-guanosine monophosphate-specific phosphodiesterase selectively vasodilates
the pulmonary circulation in chronically hypoxic rats. J Clin Invest 97:172-179
Corbin JD, Beasley A, Blount MA, Francis SH (2005) High lung PDE5: a strong basis for
treating pulmonary hypertension with PDE5 inhibitors. Biochem Biophys Res Commun
334:930-938
D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP,
Goldring RM, Groves BM, Kernis JT et al (1991) Survival in patients with primary pulmonary
hypertension. Results from a national prospective registry. Ann Intern Med 115:343-349
Deb B, Bradford K, Pearl RG (2000) Additive effects of inhaled nitric oxide and intravenous
milrinone in experimental pulmonary hypertension. Crit Care Med 28:795-799
Dempsie Y, Morecroft I, Welsh DJ, MacRitchie NA, Herold N, Loughlin L, Nilsen M, Peacock
AJ, Harmar A, Bader M, MacLean MR (2008) Converging evidence in support of the serotonin
hypothesis of dexfenfluramine-induced pulmonary hypertension with novel transgenic mice.
Circulation 117:2928-2937
Dent G, Magnussen H, Rabe KF (1994) Cyclic nucleotide phosphodiesterases in the human lung.
Lung 172:129-146
Dolci S, Belmonte A, Santone R, Giorgi M, Pellegrini M, Carosa E, Piccione E, Lenzi A, Jannini
EA (2006) Subcellular localization and regulation of type-1C and type-5 phosphodiesterases.
Biochem Biophys Res Commun 341:837-846
Dony E, Lai YJ, Dumitrascu R, Pullamsetti SS, Savai R, Ghofrani HA, Weissmann N,
Schudt C, Flockerzi D, Seeger W, Grimminger F, Schermuly RT (2008) Partial reversal
of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition. Eur Respir J
31:599-610
Dunkerley HA, Tilley DG, Palmer D, Liu H, Jimmo SL, Maurice DH (2002) Reduced phosphodi-
esterase 3 activity and phosphodiesterase 3A level in synthetic vascular smooth muscle cells:
implications for use of phosphodiesterase 3 inhibitors in cardiovascular tissues. Mol Pharmacol
61:1033-1040
Eddahibi S, Raffestin B, Monnier L, de Gouville AC, Adnot S (1998) Effect of DMPPO, a
phosphodiesterase type 5 inhibitor, on hypoxic pulmonary hypertension in rats. Br J Pharmacol
125:681-688
Evgenov OV, Busch CJ, Evgenov NV, Liu R, Petersen B, Falkowski GE, Petho B, Vas A,
Bloch KD, Zapol WM, Ichinose F (2006) Inhibition of phosphodiesterase 1 augments the
pulmonary vasodilator response to inhaled nitric oxide in awake lambs with acute pulmonary
hypertension. Am J Physiol Lung Cell Mol Physiol 290:L723-L729
